Drug Patents Expiring in 2019

The list below is comprised of prescription medications slated for drug patent expirations in 2019. As these dates approach, Carlisle Medical will seek opportunities to transition claimants to the generic medication versions as they become available. Please note, these are anticipated generic launch dates and are subject to change.

Brand Name: Latuda
• Generic Name: Lurasidone
• Patent Expiration Date: January 2019
• Used to treat schizophrenia or bipolar disorder, also known as manic-depression.

Brand Name: Restasis
• Generic Name: Cyclosporine ophthalmic emulsion
• Patent Expiration Date: 2019
• Used to increase tear productions when suppressed tear production is presumed to be due to keratoconjunctivits sicca-associated ocular inflammation.

Brand Name: Ranexa
• Generic Name: Ranolazine
• Patent Expiration Date: February 2019
• Used to treat chronic chest pain.

Brand Name: Vesicare
• Generic Name: Solifenacin succinate
• Patent Expiration Date: May 2019
• Used to treat overactive bladder.

Brand Name: Lyrica
• Generic Name: Pregabalin
• Patent Expiration Date: July 2019
• Used to treat nerve pain from diabetes, shingles, spinal cord injury, and fibromyalgia. It is also used to control seizures in epilepsy.

Brand Name: Suboxone sublingual film
• Generic Name: Buprenorphine/Naloxone sublingual film
• Patent Expiration Date: 2020 or earlier.
• Used to treat certain types of drug dependence.

Please contact us at 800-553-1783 or at pharmacy@carlislemedical.com if you have any questions on this announcement or if our pharmacy staff may assist you in any way.